Vaxart (NASDAQ:VXRT) Stock Price Crosses Below 200 Day Moving Average - Here's Why

Key Points

• Vaxart's share price fell below its 200-day moving average of $0.47, trading as low as $0.36 amidst a volume of 319,475 shares.
• Analysts have upgraded Vaxart’s rating to "hold," with a reported earnings per share (EPS) of ($0.07) meeting expectations and a revenue of $20.88 million for the last quarter.
• Insider Steven Lo purchased 100,000 shares at $0.49, showing confidence in the company's future, while institutional investors now own 18.05% of the company's stock.

Shares of Vaxart, Inc. (NASDAQ:VXRT - Get Free Report) crossed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $0.47 and traded as low as $0.36. Vaxart shares last traded at $0.36, with a volume of 319,475 shares.

Wall Street Analyst Weigh In

Separately, Wall Street Zen upgraded shares of Vaxart to a "hold" rating in a report on Thursday, May 22nd. One investment analyst has rated the stock with a Buy rating, Based on data from MarketBeat, the stock has an average rating of "Buy" and an average price target of $2.00.

Vaxart Stock Up 0.7%

The company has a fifty day moving average of $0.44 and a 200 day moving average of $0.46. The company has a market cap of $84.01 million, a P/E ratio of -1.36 and a beta of 1.12.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Marshall Wace LLP purchased a new position in Vaxart during the second quarter valued at $794,000. Jones Financial Companies Lllp lifted its holdings in shares of Vaxart by 276,364.7% in the 1st quarter. Jones Financial Companies Lllp now owns 478,284 shares of the biotechnology company's stock worth $196,000 after acquiring an additional 478,111 shares during the last quarter. Squarepoint Ops LLC boosted its position in shares of Vaxart by 95.0% during the fourth quarter. Squarepoint Ops LLC now owns 516,798 shares of the biotechnology company's stock valued at $342,000 after buying an additional 251,789 shares during the period. Raymond James Financial Inc. purchased a new stake in Vaxart in the fourth quarter worth $129,000. Finally, Virtu Financial LLC bought a new stake in Vaxart during the 1st quarter valued at about $56,000. 18.05% of the stock is owned by hedge funds and other institutional investors.

Vaxart Company Profile

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.